Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen

Verschraegen, Claire F.; Arias-Pulido, Hugo; Lee, S. J.; Movva, Sujana; Cerilli, Lisa A.; Eberhardt, S.; Schmit, Berndt P.; Quinn, Robert H.; Muller, Carolyn Y.; Rabinowitz, Ian; Purdy, M.; Snyder, David S.; Bocklage, Thèrése

doi:10.1093/annonc/mdr299

Cited by 66 publications

(51 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results from a phase 1B study of gemcitabine-docetaxel plus bevacizumab for patients with chemo-naïve soft tissue sarcoma had previously demonstrated an objective response rate reaching 31%, with a median duration of response of 6 months [34]. …”

Section: Systemic Therapymentioning

confidence: 99%

The role of adjuvant therapy in uterine leiomyosarcoma

Ducie

Leitao

2015

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Summary Uterine leiomyosarcoma (uLMS) is a rare mesenchymal tumor of the gynecologic tract. Although diagnosed in only 1-3% of patients with uterine cancer, uLMS accounts for the majority of uterine cancer-related deaths. The standard of care for patients with uLMS includes total hysterectomy and bilateral salpingo-oophorectomy (BSO). There are no standard recommendations regarding adjuvant or palliative therapy. Many cytotoxic and targeted agents have been studied in clinical trials in an effort to identify an effective therapy that may alter the natural history of this disease. Unfortunately, as of now, there are no adjuvant therapy regimens that improve overall survival in this patient population. There is, therefore, an unmet need to identify a novel therapy that will improve the survival of women diagnosed with this aggressive disease. The current review aims to summarize the existing literature on adjuvant therapy in uLMS, specifically highlighting advances made in the last 5 years.

show abstract

Section: Systemic Therapymentioning

confidence: 99%

The role of adjuvant therapy in uterine leiomyosarcoma

Ducie

Leitao

2015

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

show abstract

“…In a Phase I/II study bevacizumab (5 mg/kg) was added to gemcitabine (1000 --1500 mg/m 2 ) and docetaxel (50 mg/m 2 ) every 2 weeks to 38 chemonaive-patients with advanced STS [99]. OR and SD lasting for a median of 6 months were achieved in 31.4 and 47.3% of the patients, respectively.…”

Section: Bevacizumab and Afliberceptmentioning

confidence: 99%

Pharmacological treatment for uterine leiomyosarcomas

Gadducci

Guerrieri

2014

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

DOX alone, gemcitabine alone, DOX + dacarbazine and gemcitabine + docetaxel may be treatment options for first-line and second-line therapies. However, the clinical benefit of the combination chemotherapy versus single-agent chemotherapy is still debated. Trabectedin is a promising agent for recurrent uterine LMS, able to obtain a prolonged disease control, with 3-month and 6-month progression-free survival rates exceeding 50 and 30%, respectively, and with sometimes unexpectedly durable responses. Pazopanib is the only approved targeted therapy. Hormone therapy with aromatase inhibitors may be a therapeutic option in heavily treated patients with slowly progressive, steroid receptor-positive tumors. Whenever possible, women with recurrent uterine LMS should be encouraged to enter well-designed clinical trials aimed to detect novel active agents.

show abstract

“…Combination regimens using gemcitabine and docetaxel (Gem/Doce) have proven to be effective in STS, especially when used in uterine and nonuterine leiomyosarcoma [21,22,23,24], but are formally not approved for STS treatment. Thus far, there are no available data on the efficacy of Gem/Doce for ES.…”

Section: Introductionmentioning

confidence: 99%

Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis

Pink¹,

Richter

Gerdes

et al. 2014

Oncology

View full text Add to dashboard Cite

Objective: Epithelioid sarcoma (ES) presents unique clinical features in comparison to other sarcoma subtypes. Data regarding the benefits of chemotherapy are very limited. Combination regimens using gemcitabine and docetaxel (Gem/Doce) have proven to be effective, especially in uterine and nonuterine leiomyosarcoma. Yet, there is no available data on the efficacy of Gem/Doce in ES. Methods: A retrospective analysis of the three participating institutions was performed. Twenty-eight patients with an ES diagnosis presented at one of the participating institutions between 1989 and 2012. Of this group, 17 patients received chemotherapy. Results: Patients' median overall survival (OS) after the beginning of palliative chemotherapy was 21 months, and the 1-year OS was 87%. Twelve patients received Gem/Doce with a clinical benefit rate of 83%. The median progression-free survival (PFS) was 8 months for all patients receiving Gem/Doce. The best response was complete remission in 1 patient and partial remission in 6 patients. All 6 patients receiving Gem/Doce as a first-line treatment showed measurable responses with a median PFS of 9 months. Conclusions: In this retrospective study, Gem/Doce was an effective chemotherapeutic regimen for ES. Prospective studies are needed to better assess the effects of this combination drug therapy.

show abstract

Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen

Cited by 66 publications

References 39 publications

The role of adjuvant therapy in uterine leiomyosarcoma

The role of adjuvant therapy in uterine leiomyosarcoma

Pharmacological treatment for uterine leiomyosarcomas

Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis

Contact Info

Product

Resources

About